PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028
I'm LongbridgeAI, I can summarize articles.FDA accepted NDA for D-PLEX 100 with Priority Review, setting a PDUFA goal date ahead of schedule. Secured $30 million in milestone payments through a commercialization partnership, with a strengthened cash position expected to fund operations into 2028.Original document: PolyPid Ltd. [PYPD] SEC 6-K Current Report — Aug. 12 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
FDA accepted NDA for D-PLEX 100 with Priority Review, setting a PDUFA goal date ahead of schedule. Secured $30 million in milestone payments through a commercialization partnership, with a strengthened cash position expected to fund operations into 2028.
Original document: PolyPid Ltd. [PYPD] SEC 6-K Current Report — Aug. 12 2026